CroiValve

CroíValve is a private, clinical-stage medical device company targeting the significant unmet need in tricuspid regurgitation (TR). The company's core innovation is the DUO™ System, a transcatheter device engineered to coapt with the native valve leaflets, aiming to offer a simpler, more anatomical solution compared to existing repair or replacement approaches. With a seasoned leadership team combining clinical, technical, and commercial expertise, CroíValve is advancing its technology through clinical studies. The company operates in a high-growth potential market but faces competition and the inherent risks of device development and regulatory pathways.

Transcatheter coaptation assistance device for the tricuspid valve, designed to work with native anatomy rather than replacing it.

The transcatheter tricuspid intervention space is competitive and includes large players like Abbott (TriClip), Edwards Lifesciences (EVOQUE, Pascal), and Boston Scientific, alongside other startups. CroíValve's key differentiation is its coaptation assistance mechanism, which is distinct from leaflet repair (TEER) or valve replacement (TTVR) technologies, potentially offering a middle-ground solution.